Dr. Van Bokkelen will provide a brief overview of the Athersys’ clinical pipeline, focusing on the ongoing Phase 3 trial of MultiStem® cell therapy for the treatment of ischemic stroke that has received Fast Track and RMAT designation from the U.S. Food and Drug Administration, positive scientific advice from the European Medicines Agency, and is being conducted under a Special Protocol Assessment (SPA).
In addition, Dr. Van Bokkelen has been invited to speak at two conference workshops, where he will describe the Company’s progress working in collaboration with Healios K.K. under the innovative regenerative medicine regulatory framework implemented in Japan as part of the “Doing Business in Japan” workshop. During the “Readiness Strategies for Cell Therapy – Commercial Manufacturing” workshop, Dr. Van Bokkelen will discuss commercial manufacturing approaches and technologies for cellular therapies.
Event: Doing Business in Japan Workshop: Development of an “Off the Shelf” Cell Therapy for Ischemic Stroke and Other Indications Under the Regenerative Medicine Regulatory Framework in Japan
Date: October 3, 2018
Time: 7:50 – 8:05 am Pacific Time
Location: Magnolia Room at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
Event: Athersys Corporate Overview
Date: October 3, 2018
Time: 5:30 – 5:45 pm Pacific Time
Location: Ballroom 1 at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
Event: Readiness Strategies for Cell Therapy – Commercial Manufacturing Workshop, Section 3 Technology
Date: October 4, 2018
Time: 8:10 – 8:35 am Pacific Time
Location: Learning Theater at the Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 9203